A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses

Abstract

The PPAR-gamma agonist triterpenoid CDDO attenuates fibrogenesis by antagonistically targeting canonical TGF-Beta/Smad and Akt signalling in a PPAR-gamma- independent manner. These findings identify this synthetic triterpenoid as a potential new therapy for the control of fibrosis.

Keywords

• systemic sclerosis
• fibrosis
• PPAR-gamma
• CDDO